(Q46592548)

23 December 2017

title

Endogenous dopamine (DA) renders dopaminergic cells vulnerable to challenge of proteasome inhibitor MG132. (English)

1 reference

23 December 2017

1 reference

Zhidong Zhou

1

1 reference

23 December 2017

Szeyen Kerk

series ordinal

2

1 reference

23 December 2017

Tit Meng Lim

series ordinal

3

1 reference

23 December 2017

publication date

1 May 2008

1 reference

23 December 2017

published in

Free Radical Research

1 reference

23 December 2017

volume

42

1 reference

23 December 2017

issue

5

1 reference

23 December 2017

page(s)

456-466

1 reference

23 December 2017

Mapping of a gene for Parkinson's disease to chromosome 4q21-q23

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Ubiquitin-proteasome system and Parkinson's diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Proteasome inhibitor MG-132 induces dopaminergic degeneration in cell culture and animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

L-dopa and dopamine enhance the formation of aggregates under proteasome inhibition in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Inhibition of proteasome activity sensitizes dopamine neurons to protein alterations and oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Dopamine induces proteasome inhibition in neural PC12 cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Failure of proteasome inhibitor administration to provide a model of Parkinson's disease in rats and monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Proteasome inhibitors protect against degeneration of nigral dopaminergic neurons in hemiparkinsonian rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Immortalization of embryonic mesencephalic dopaminergic neurons by somatic cell fusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Neuronal-enriched cultures from embryonic rat ventral mesencephalon for pharmacological studies of dopamine neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Metal-catalyzed oxidation of protein-bound dopamine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

Dopamine covalently modifies and functionally inactivates parkin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10715760802005177

10.1080/10715760802005177

21 January 2018

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017